References
1. World Health Organization (WHO). Novel Coronavirus (2019-nCoV),
Situation Report - 1, 21 January 2020 . WHO; 2020.
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
2. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory
syndrome-related coronavirus</em>: The species
and its viruses – a statement of the Coronavirus Study Group.bioRxiv . 2020:2020.02.07.937862. doi:10.1101/2020.02.07.937862
3. Mahase E. Covid-19: most patients require mechanical ventilation in
first 24 hours of critical care. BMJ . Mar 24 2020;368:m1201.
doi:10.1136/bmj.m1201
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet . Feb 15
2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
5. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically
Ill Patients in the Seattle Region - Case Series. N Engl J Med .
Mar 30 2020;doi:10.1056/NEJMoa2004500
6. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the
COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast
During an Emergency Response. JAMA . Mar 13
2020;doi:10.1001/jama.2020.4031
7. Kirkland SW, Soleimani A, Rowe BH, Newton AS. A systematic review
examining the impact of redirecting low-acuity patients seeking
emergency department care: is the juice worth the squeeze? Emerg
Med J . Feb 2019;36(2):97-106. doi:10.1136/emermed-2017-207045
8. Rowe BH, Guo X, Villa-Roel C, et al. The role of triage liaison
physicians on mitigating overcrowding in emergency departments: a
systematic review. Acad Emerg Med . Feb 2011;18(2):111-20.
doi:10.1111/j.1553-2712.2010.00984.x
9. Morley C, Unwin M, Peterson GM, Stankovich J, Kinsman L. Emergency
department crowding: A systematic review of causes, consequences and
solutions. PLoS One . 2018;13(8):e0203316.
doi:10.1371/journal.pone.0203316
10. World Health Organization Director. General’s opening remarks
at the media briefing on COVID-19 - 24 February 2020 . 2020. Accessed 07
April 2020.
https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---24-february-2020
11. Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical
Trials. JAMA . Jul 25 2019;doi:10.1001/jama.2019.9892
12. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation
and elaboration: guidance for protocols of clinical trials. BMJ .
Jan 8 2013;346:e7586. doi:10.1136/bmj.e7586
13. Food and Drug Administration. Surrogate Endpoint Resources for
Drug and Biologic Development . 2018. Accessed 10 April 2020.
https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development
14. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are
we being misled? Ann Intern Med . Oct 1 1996;125(7):605-13.
doi:10.7326/0003-4819-125-7-199610010-00011
15. Food and Drug Administration. Amendments Act of 2007. Public
Law 110-85.
16. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The
ClinicalTrials.gov results database–update and key issues. N
Engl J Med . Mar 3 2011;364(9):852-60. doi:10.1056/NEJMsa1012065
10.1056/NEJMsa1012065.
17. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus (2019-nCoV)
in vitro. Cell Res . Mar 2020;30(3):269-271.
doi:10.1038/s41422-020-0282-0
18. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and
azithromycin as a treatment of COVID-19: results of an open-label
non-randomized clinical trial. Int J Antimicrob Agents . Mar 20
2020:105949. doi:10.1016/j.ijantimicag.2020.105949
19. Food and Drug Administration. Request for Emergency Use
Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine
Sulfate Supplied From the Strategic National Stockpile for Treatment of
2019 Coronavirus Disease . 2020. Accessed 07 April 2020.
https://www.fda.gov/media/136534/download
20. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs:
Plaquenil . Accessed 07 April 2020.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768
21. Lehoux P, Miller FA, Daudelin G, Denis JL. Providing Value to New
Health Technology: The Early Contribution of Entrepreneurs, Investors,
and Regulatory Agencies. Int J Health Policy Manag . Sep 1
2017;6(9):509-518. doi:10.15171/ijhpm.2017.11
22. Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 research has
overall low methodological quality thus far: case in point for
chloroquine/hydroxychloroquine. Journal of Clinical Epidemiology .
2020;doi:10.1016/j.jclinepi.2020.04.016
23. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook:
version 1.0. Trials . Jun 20 2017;18(Suppl 3):280.
doi:10.1186/s13063-017-1978-4
24. Bikdeli B, Punnanithinont N, Akram Y, et al. Two Decades of
Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.J Am Heart Assoc . Mar 21 2017;6(3)doi:10.1161/JAHA.116.005285
25. Yazdany J, Kim AHJ. Use of Hydroxychloroquine and Chloroquine During
the COVID-19 Pandemic: What Every Clinician Should Know. Ann
Intern Med . Mar 31 2020;doi:10.7326/M20-1334
26. Zarin DA, Tse T, Williams RJ, Carr S. Trial Reporting in
ClinicalTrials.gov - The Final Rule. N Engl J Med . Nov 17
2016;375(20):1998-2004. doi:10.1056/NEJMsr1611785
27. CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association;
c2016 [updated 2020 April; cited 2020 April 15]. Gleevec
[Hydroxychloroquine]. Available from: http://www.e-cps.ca or
http://www.myrxtx.ca. Also available in paper copy from the
publisher.
28. Mayo-Wilson E, Fusco N, Li T, et al. Harms are assessed
inconsistently and reported inadequately part 1: systematic adverse
events. J Clin Epidemiol . Sep 2019;113:20-27.
doi:10.1016/j.jclinepi.2019.04.022
29. Mayo-Wilson E, Fusco N, Hong H, Li T, Canner JK, Dickersin K.
Opportunities for selective reporting of harms in randomized clinical
trials: Selection criteria for non-systematic adverse events.Trials . Sep 5 2019;20(1):553. doi:10.1186/s13063-019-3581-3
30. Ghersi D, Pang T. From Mexico to Mali: four years in the history of
clinical trial registration. J Evid Based Med . Feb 2009;2(1):1-7.
doi:10.1111/j.1756-5391.2009.01014.x